Isa Pharmaceuticals – Immune System Activation
  • nl
  • fr
  • de
  • Home
  • Company
    • Company Milestones
    • Strategy
    • Management
    • Supervisory Board
    • Advisory Board
  • Pipeline
    • Pipeline Chart
    • Pipeline Overview
  • Clinical Studies
  • Technology
    • SLP® Concept
    • Publications
    • Technology Overview
  • News & Events
    • News Archive
    • Upcoming Events
  • Job Openings
  • Contact
    • Imprint / Disclaimer

Immunotherapeutics against cancer and infectious diseases

ISA Pharmaceuticals B.V. is developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections.

Read more

News

  • November 13, 2018

    ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018

  • September 27, 2018

    ISA Pharmaceuticals Reports Publication of Favorable Phase 2 Results of ISA101 plus Nivolumab in JAMA Oncology

Events

  • December 2 – 5, 2018

    Eurogin 2018

  • January 7 – 10, 2019

    J.P. Morgan 37th Annual Healthcare Conference

Latest Publications

  • September 5, 2016
    Cancer Research / Science Translational Medicine

    Cancer Research / Science Translational Medicine

More news
More events
More publications
Loading Quotes...
© ISA Pharmaceuticals B.V. all rights reserved
  • Contact
  • Sitemap
  • Imprint / Disclaimer